PT Charlie Hospital Semarang Tbk (RSCH) Fair Value & Analysis
Healthcare · ID · Market cap 678B IDR
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from 147.76 IDR to 33.00 IDR (−77.7%) since Jun 24, 2026. Share price +12.8% over the past month.
Below-average quality, and screening another 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (49.25 IDR). The favourable scenario is already priced in.
- Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (24.63 IDR to 49.25 IDR) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
35‑month range 117.00 IDR – 490.00 IDR · fair‑value band 24.63 IDR – 49.25 IDR · the 318.00 IDR price screens above the 33.00 IDR fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
PT Charlie Hospital Semarang Tbk (RSCH) currently trades at 318.00 IDR, while our model-based Fair Value estimate is 33.00 IDR, implying the stock looks roughly 89.6% overvalued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, PT Charlie Hospital Semarang Tbk generated revenue of 118B IDR at a net margin of -12.2%. Revenue grew 29.2% year over year. It earns a return on equity of -10.8%. Fundamentals as of Jul 16, 2026
Our scenario range runs from 24.63 IDR (bear case) to 49.25 IDR (bull case); at 318.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -90%, RSCH screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when RSCH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Charlie Hospital Semarang Tbk operates private hospitals in Indonesia. It operates through Healthcare Services, Construction Services, and Construction Materials Trading segments.
Full company description
PT Charlie Hospital Semarang Tbk operates private hospitals in Indonesia. It operates through Healthcare Services, Construction Services, and Construction Materials Trading segments. The company's hospitals offer outpatients and inpatient services, including a 24-hour emergency room, specialist polyclinic services, central surgical installation services, intensive care units, Perina, laboratory services, radiology services, pharmacy services, medical checkup and support services, wellness centers, and other supporting facilities. It also engages in the construction, maintenance, and reconstruction of residential, office, industrial, commercial, healthcare, educational, lodging, entertainment/sports, and other buildings; and trading of construction materials. The company was founded in 2019 and is headquartered in Kendal, Indonesia. PT Charlie Hospital Semarang Tbk operates as a subsidiary of PT Wahyu Agung.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
PT Charlie Hospital Semarang Tbk reported revenue of 114B IDR in FY2025 versus 33.0B IDR in FY2022, a compound +51.3%/yr. Reported net income was −16.4B IDR in FY2025.
RSCH screens 90% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Charlie Hospital Semarang Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Charlie Hospital Semarang Tbk (RSCH) overvalued or undervalued?
What is the fair value of RSCH?
What is the quality score of RSCH?
What is the revenue of PT Charlie Hospital Semarang Tbk (RSCH)?
What is the net profit margin of RSCH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Charlie Hospital Semarang Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.